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Abstract: The bioavailability of orally administered drugs could be impacted by intestinal and hepatic
first-pass metabolism. Testosterone undecanoate (TU), an orally administered ester prodrug of
testosterone, is significantly subjected to first-pass metabolism. However, the individual contribution
of intestinal and hepatic first-pass metabolism is not well determined. Therefore, the aim of the
current study was to predict the metabolic contribution of each site. The hydrolysis–time profiles of
TU incubation in human liver microsomes and Caco-2 cell homogenate were used to predict hepatic
and intestinal first-pass metabolism, respectively. The in vitro half-life (t1/2 inv) for the hydrolysis of
TU in microsomal mixtures was 28.31 ± 3.51 min. By applying the “well-stirred” model, the fraction
of TU that could escape hepatic first-pass metabolism (FH) was predicted as 0.915 ± 0.009. The
incubation of TU in Caco-2 cell homogenate yielded t1/2 inv of 109.28 ± 21.42 min, which was applied
in a “Q gut” model to estimate the fraction of TU that would escape intestinal first-pass metabolism
(FG) as 0.114 ± 0.02. Accordingly, only 11% of the absorbed fraction of TU could escape intestinal
metabolism, while 91% can pass through hepatic metabolism. Hence, compared to the liver, the
intestinal wall is the main site where TU is significantly metabolised during first-pass effect.
Keywords: testosterone undecanoate; first-pass metabolism; bioavailability; human liver microsomes;
Caco-2 cells
1. Introduction
Testosterone undecanoate (TU, Figure 1) is an ester prodrug of the anabolic steroid, testosterone.
TU was introduced in the late 1970s as an effective oral testosterone replacement therapy [1,2]. In fact,
testosterone is well absorbed from the intestinal lumen. However, therapeutic plasma levels following
oral administration of testosterone cannot be achieved due to extensive first-pass metabolism [3].
Therefore, TU and other testosterone prodrugs have been proposed to reach effective levels of
testosterone by avoiding pre-systemic metabolism and/or to provide more flexible therapeutic options
in terms of the route of administration, and stability of plasma levels attained [4]. Once absorbed to the
systemic circulation, the undecanoate side chain of TU is cleaved by the action of non-specific plasma
esterase to release testosterone [5]. Currently, TU is commercially available as oral capsules, Andriol
Testocaps® and Jatenzo®, and intramuscular injections, Aveed® and Nebido®. These formulations
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are commonly used in the treatment of male hypogonadal disorders characterized by low serum levels
of testosterone [6].
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Coert and colleagues have demonstrated that the metabolism of TU starts in the intestinal wall of 
rats, and part of the fraction that escapes intestinal metabolism is absorbed via the intestinal 
lymphatics [7]. Geelen et al. have also shown that TU is metabolised in the intestinal wall, as 
metabolites of TU could be detected in the portal vein of rats [8]. In lymph duct-cannulated dogs, it 
was shown that the bioavailability of orally administered TU was as low as 3%, almost all of which 
was absorbed through intestinal lymphatics [9]. In humans, Horst et al. have placed thoracic duct 
catheters in four participants following neck dissection for the resection of left mouth tumours [10]. 
In that study, following the oral administration of radiolabelled TU, the thoracic lymph was rich with 
TU and its main metabolite 5α-dihydrotestosterone undecanoate (5α-DHTU). However, both were 
undetectable in the systemic circulation. It should be mentioned that 5α-DHTU is a product of the 
metabolic activity of 5α-reductase on TU. Several other human studies have also suggested that 
lymphatically transported TU is the main source of testosterone in the systemic circulation [11–13], 
and the bioavailability of testosterone increases as the fat-content of the co-administered food 
increases [14]. To note, fatty-food increases intestinal lymphatic delivery of lipophilic drugs that have 
high lymphatic transport potential [15]. However, the systemic bioavailability of testosterone 
following the oral administration of TU in conditions that facilitate intestinal lymphatic transport was 
still as low as 6.8% in humans [1]. 
Taking together the above-mentioned observations, it is now well established that the intestinal 
wall contributes to the metabolism of TU. The fraction that survives intestinal first-pass metabolism 
is partly absorbed through the lymphatic system while the remaining part is delivered via the portal 
vein to the liver where it is substantially metabolised [16]. Both intestinal and hepatic first-pass 
metabolism contribute to the low bioavailability of TU. However, the relative contribution of each 
metabolic site (intestinal wall versus liver) is still unclear. Once the major site of TU metabolism is 
revealed, a clear insight for an approach to improve the bioavailability of TU could be achieved. 
Therefore, the aim of the current study was to predict the individual impact of intestinal and hepatic 
first-pass metabolism on the bioavailability of orally administered TU. 
2. Materials and Methods 
2.1. Materials 
Testosterone undecanoate (TU; CAS: 5949-44-0; purity: 99%) was bought from Beijing Sjar 
Technology Development Co., Ltd. (Beijing, China). Vitamin D3 (CAS: 67-97-0; purity: 99%) was 
purchased from Alfa Aesar (Lancashire, UK). KH2PO4, K2HPO4, MgCl2, and NH₄CH₃CO₂ were 
purchased from Sigma (Dorset, UK). Nicotinamide adenine dinucleotide phosphate tetrasodium salt 
hydrate (NADPH) was bought from Fisher Scientific (Leicestershire, UK). Liver microsomes from 
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Several animal studies have explored the mechanisms involved in the oral bioavailability of TU.
Coert and colleagues have demonstrated that the metabolism of TU starts in the intestinal wall of rats,
and part of the fraction that escapes intestinal metabolism is absorbed via the intestinal lymphatics [7].
Geelen et al. have also shown that TU is metabolised in the intestinal wall, as metabolites of TU
could be detected in the portal vein of rats [8]. In lymph duct-cannulated dogs, it was shown that the
bioavailability of orally administered TU was as low as 3%, almost all of which was absorbed through
intestinal lymphatics [9]. In humans, Horst et al. have placed thoracic duct catheters in four participants
following neck dissection for the resection of left mouth tumours [10]. In that study, following the
oral administration of radiolabelled TU, the thoracic lymph was rich with TU and its main metabolite
5α-dihydrotestosterone undecanoate (5α-DHTU). However, both were undetectable in the systemic
circulation. It should be mentioned that 5α-DHTU is a product of the metabolic activity of 5α-reductase
on TU. Several other human studies have also suggested that lymphatically transported TU is the
main source of testosterone in the systemic circulation [11–13], and the bioavailability of testosterone
increases as the fat-content of the co-administered food increases [14]. To note, fatty-food increases
intestinal lymphatic delivery of lipophilic drugs that have high lymphatic transport potential [15].
However, the systemic bioavailability of testosterone following the oral administration of TU in
conditions that facilitate intestinal lymphatic transport was still as low as 6.8% in humans [1].
Taking together the above-mentioned observations, it is now well established that the intestinal
wall contributes to the metabolism of TU. The fraction that survives intestinal first-pass metabolism is
partly absorbed through the lymphatic system while the remaining part is delivered via the portal vein
to the liver where it is substantially metabolised [16]. Both intestinal and hepatic first-pass metabolism
contribute to the low bioavailability of TU. However, the relative contribution of each metabolic site
(intestinal wall versus liver) is still unclear. Once the major site of TU metabolism is revealed, a clear
insight for an approach to improve the bioavailability of TU could be achieved. Therefore, the aim of
the current study was to predict the individual impact of intestinal and hepatic first-pass metabolism
on the bioavailability of orally administered TU.
2. Materials and Methods
1. Materials
Testosterone undecanoate (TU; CAS: 5949-44-0; purity: 99%) was bought from Beijing Sjar
Technology Development Co., Ltd. (Beijing, China). Vitamin D3 (CAS: 67-97-0; purity: 99%) was
purcha ed from Alfa Aesar (Lancashire, UK). KH2PO4, K2HPO4, MgCl2, and NH4CH3CO2 were
purchased from Sigma (Dorset, UK). Nicotinamide denine di ucleotide phosphate tetrasodium salt
hydrate (NADPH) was bought from Fisher Scientific (Leicestershire, UK). Liver microsomes from
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human donors were obtained from Gibco Invitrogen (Paisley, UK). Caco-2 cells (passage number 47)
were obtained from Cell Culture Collections, Public Health England (Salisbury, UK). Dulbecco’s
modified eagle medium (DMEM) supplemented with GlutaMAX™, 4.5 g/L D-glucose and 25 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer was obtained from Gibco (Paisley,
UK). Hank’s balanced salt solution (HBSS), HEPES buffer, fetal bovine serum (FBS), and all compounds
used in the study were obtained from Sigma (Gillingham, UK). All other reagents were of analytical
grade or higher.
2.2. Prediction of Hepatic First-Pass Metabolism
Microsomal metabolism stability studies were conducted to predict the fraction of TU that
could escape hepatic first-pass metabolism (FH). Stability studies were performed using human liver
microsomes. The in vitro intrinsic clearance (Clint, mL/min/mg protein) was calculated using the
in vitro half-life (t1/2 inv) of TU depletion in human liver microsomes according to Equation (1) [17,18].
Clint =
0.693
in vitro t1/2
·mL, incubation medium
mg, microsomes
(1)
Microsomal incubations were performed as previously described [17]. Briefly, the reaction mixture
consisted of human microsomal proteins and MgCl2 dissolved in solution a of potassium phosphate
buffer (KH2PO4/K2HPO4, pH 7.4). TU was accurately weighed and dissolved in aqueous acetonitrile
(50% v/v). Reaction tubes containing the reaction mixture were placed in a temperature-controlled
orbital shaker at 37 ◦C and shaken at 200 rpm (Thermo Scientific MaxQ4000, Waltham, MA, USA).
Following a pre-incubation period of 3 min, the reaction was initiated by the addition of TU and the
NADPH solution in the potassium phosphate buffer. TU solution in potassium phosphate buffer
without NADPH was added to another set of reaction tubes as a control. The concentration of
acetonitrile in the final mixture was less than 1%. The final concentrations of TU, human liver
microsomes, MgCl2, KH2PO4/K2HPO4, and NADHP were 1 µM, 0.5 mg/mL, 10 mM, 84.7 mM, and
1 mM, respectively. Two-hundred microlitre aliquots were withdrawn at 0 min, 10 min, 20 min, and
30 min and placed in a test tube that contained 300 µL ice-cold acetonitrile to stop the reaction. Samples
were then processed on the same day for high-performance liquid chromatography (HPLC) analysis as
described below. All experiments were performed in triplicates.
Clint was then corrected by the fraction of drug unbound in the incubation medium (fu,mic)
according to Equation (2) to find the unbound intrinsic clearance (Clu,int) [19].
Clu,int =
Clint
fu,mic
(2)
The experimental determination of fu,mic for highly lipophilic drugs is quite challenging due to
significant non-specific binding [20]. In addition, predictive tools for fu,mic, such as those suggested by
Austin et al. [21] and Hallifax and Houston [22], were demonstrated to be unreliable for drugs with a
logP value ≥ 5 such as TU (logP = 9.15 [23]) [20]. Therefore, the binding of TU to microsomal proteins
was assumed to be similar to that of plasma proteins, corrected by protein concentration [18]. Based on
this, fu,mic was calculated by Equation (3) [24].
fu,mic =
1(
Cmic
Cpp ×
(1− fu,p)
fu,p
)
+ 1
(3)
where Cmic is the microsomal protein concentration (0.5 mg/mL), Cpp is the concentration of human
plasma proteins (70 mg/mL [25]), and fu,p is the fraction of TU unbound in human plasma. The value
of fu,p for TU was estimated by the online prediction tool (https://drumap.nibiohn.go.jp/) [26].
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The calculated value of Clu,inc was then scaled, based on human physiological factors of 32 mg
microsomes/g liver and 22 g liver/kg body weight [18,27,28], to find the hepatic intrinsic clearance
(ClH,inc, mL/min/kg). Hepatic clearance (ClH) was then calculated assuming a well-stirred model using
Equation (4)
ClH =
Q × fu,p × ClH, inc
Q+ fu,p × ClH, inc (4)
where Q is liver blood flow (21 mL/min/kg) [29].
Finally, FH was calculated from ClH as indicated in Equation (5)
FH = (1− ClH/Q) (5)
2.3. Prediction of Intestinal First-Pass Metabolism
2.3.1. Preparation of Caco-2 Cell Homogenate
Caco-2 cells (passage numbers 53) were seeded in 75 cm2 cell culture flasks (Corning Inc, Corning,
NY, USA) at 3.75 × 104 cells/cm2 and cultured in DMEM supplemented with 10% FBS and 1%
penicillin-streptomycin. Cells were kept at 37 ◦C, 95% relative humidity, and 5% CO2. The medium
was replaced three times a week for 21 days. Confluent cells were then scraped and washed twice
with phosphate buffer saline. Cells were lysed by ultrasonication on ice followed by centrifugation at
10,000× g for 5 min at 4 ◦C. Bradford assay was used to determine the protein content of the supernatant
according to the manufacturer protocol (Alfa Aesar, Lancashire, UK). Protein concentration was diluted
to 1 mg/mL for the hydrolysis study.
2.3.2. Hydrolysis Experiments
Human intestinal Caco-2 cell homogenates were used to assess the stability of TU; Caco-2
cell homogenate was previously shown to be an equivalent alternative to human small intestinal
homogenate for ester prodrug stability studies [30]. Clint (mL/min/mg protein) was calculated from the
in vitro half-life (t1/2 inv), which was measured from the first-order depletion constant of TU incubation
in human intestinal Caco-2 cell homogenate. Hydrolysis experiments were performed as previously
described [31]. Briefly, cell homogenates were spiked with TU to give a final concentration of 10 µM.
The reaction mixtures were incubated at 37 ◦C and shaken at 200 rpm for 1 h. Samples were withdrawn
at 0 min, 15 min, 30 min, 45 min, and 60 min time points. The reaction was then immediately terminated
by the addition of ice-cold acetonitrile. Samples were processed on the same day for HPLC analysis,
as described below. Hydrolysis experiments were performed in quadruplets.
Clint was then corrected by fu,mic to findClu,int (mL/min/mg protein) as described for the microsomal
stability studies using Equations (2) and (3). The calculated value of Clu,inc was then scaled, based
on human physiological factors for the total weight of enterocytes in the small intestine, to calculate
gut intrinsic clearance (ClG,int, L/h). It was previously determined that average regional weights of
enterocytes in the duodenal, jejunal, and ileal parts of the small intestine are 18.2 g, 65.8 g, and 38.3 g,
respectively [32].
The fraction of TU that could escape intestinal first-pass metabolism (FG) was estimated using the
“Q gut” model as detailed in Equation (6) [33]:
FG =
Qvilli
Qvilli + fu,G . ClG, int·(1 +Qvilli/ClPerm) (6)
where Qvilli is the villous blood flow (18 L/h) [34], Clperm is the permeability across enterocytes, and fu,G
is the fraction of drug unbound to enterocytes, which was assumed to be 1 as this value has been
shown to give the most accurate prediction [33].
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Clperm was calculated from the effective intestinal permeability (Peff) of TU and net cylindrical
surface area of the small intestine (S, 0.66 m2) using Equation (7) [33].
Cl perm = Peff·S (7)
2.4. Analytical Methods
The concentrations of TU in microsomal mixtures and Caco-2 cell homogenates were determined
by Waters Alliance 2695 HPLC system equipped with Waters 996 photodiode-array detector (Waters
Corporation, Milford, MA, USA).
2.4.1. Sample Preparation
Samples for stability studies were processed for HPLC analysis by a liquid–liquid extraction
method. Briefly, a sample volume of 200 µL from microsomal reactions and 100 µL from Caco-2
homogenates was placed in 300 µL of ice-cold acetonitrile to stop the reaction as well as precipitating
protein content [35]. Twenty microlitres of the IS (50 µm, vit D3) was added to the samples and then
vortexed for 1 min. HPLC-grade water (200 µL) was then added and the samples were vortexed again
for 1 min. n-Hexane (3 mL) was added to each tube and vortexed for 10 min. Samples were then
centrifuged at 1160× g for 10 min at room temperature (Harrier 18/80 centrifuge, MSE, London, UK).
The upper organic layer was then decanted and evaporated under N2 gas at 35 ◦C (DRI-Block type
DB-3D, Techne, Cambridge, UK). Samples were then reconstituted in 200 µL (hepatic microsomes
samples) or 100 µL (Caco-2 homogenates samples) of acetonitrile and 20 µL of the solution was then
injected into the HPLC system.
2.4.2. Chromatographic Conditions
Separation of analytes was carried out with an ACE C18 column (100 × 4.6 mm, 5 µm particle
size; Hichrom Ltd., Reading, UK), coupled with an ACE C18 3 µm guard column. Samples and
column temperatures were maintained at 5 ◦C and 50 ◦C, respectively. The mobile phase, consisting
of acetonitrile and water (96:04: v/v), was run at a flow rate of 0.5 mL/min for 20 min. The detector
wavelength was set at 240 nm. HPLC data were integrated by EmpowerTM 2 software. The peak ratios
of analyte/internal standard were normalised to the value obtained at time zero.
2.4.3. In silico Prediction of Human Effective Permeability
In vitro estimation of human effective intestinal permeability (Peff) of highly lipophilic compounds
from Caco-2 monolayers is quite challenging due to poor solubility and non-specific binding to the
in vitro system [36]. Therefore, Peff of TU was predicted using GastroPlus® software version 9.7 as
described previously [17]. Physicochemical properties of the compound were predicted by ADMET
PredictorTM. The LogD model was specified as the Structure-based version 9.5, and other settings were
set to the default settings.
2.5. Statistical Analysis
Data are presented as mean ± standard deviation (SD). An unpaired two-tailed Student’s t-test
was used to assess statistical differences between the data sets. A p value < 0.05 was considered to
represent a significant difference.
3. Results
3.1. Hepatic First-Pass Metabolism
The depletion profiles of TU in microsomal mixtures in the presence of NADPH and without
NADPH are presented in Figure 2. The in vitro half-life for the hydrolysis of TU over 30 min of
incubation in the presence of NADPH was 28.31 ± 3.51 min, and 46.8 ± 12.55 min in the absence
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of NADPH (p < 0.05). The in vitro intrinsic clearance (Clint) calculated from depletion t1/2 inv in the
presence of NADPH (Equation (1)) was 0.0497 ± 0.006 mL/min/mg protein.
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Figure 2. The hydrolysis–time profiles of testosterone undecanoate (TU) in human hepatic microsomes
in the presence of nicotinamide adenine dinucleotide phosphate tetrasodium salt hydrate (NADPH,
open symbol) and without NADPH (closed symbol). Values are expressed as mean ± SD (n = 3).
The predicted unbound fraction of TU in human plasma (fu,p) was 0.0485. This value was used
to estimate the fraction of unbound TU in the microsomal mixture (Equation (3), fu,mic = 0.877).
The correction of Clint by fu,mic (Equation (2)) gave Clu,int value of 0.0566 ± 0.006 mL/min/mg protein.
Scaling of Clu,int based on human physiological factors revealed a hepatic intrinsic clearance (ClH,inc)
of 39.89 ± 4.81 mL/min/kg. Assuming a well-stirred model, the hepatic clearance (ClH, Equation (4)) of
TU was 1.77 ± 0.19 mL/min/kg. Accordingly, it was estimated that 91% of TU would escape hepatic
first-pass metabolism (Equation (5): FH = 0.915 ± 0.009).
3.2. Intestinal First-Pass Metabolism
Caco-2 cell homogenate was used to assess the hydrolysis of TU. The hydrolysis–time profile
of TU in cell homogenate is shown in Figure 3. The in vitro half-life (t1/2 inv) for the hydrolysis of
TU was 109.28 ± 21.42 min. The value for the calculation of Clint form t1/2 inv (Equation (1)) was
0.0066 ± 0.001 mL/min/mg protein. Subsequently, Clint was corrected by fu,mic (0.781, Equation (2)) to
give Clu,int value of 0.0084 ± 0.001 mL/min/mg protein. Scaling of Clu,int to physiological factors for the
total protein weight of enterocytes in adult human (122.3 g [32]) resulted in a gut intrinsic clearance
(ClG,int) of 61.94 ± 12.07 L/h.
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The effective intestinal permeability (Peff) of TU was 5.67 × 10−4 cm/s, as predicted by GastroPlus®
software. Permeability across enterocytes (Clperm) was measured based on Equation (7) to yield 13.47
L/h. These values were applied in Equation (6) of the “Q gut” model to estimate the fraction of TU that
would escape intestinal first-pass metabolism (FG), which was 0.114 ± 0.02. Therefore, it was estimated
that only 11% of the absorbable fraction of TU could escape intestinal metabolism.
As presented in Figure 4, it is predicted that a significant fraction of TU could escape hepatic
metabolism compared with intestinal metabolism.
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4. Discussion
It is generally accepted that first-pass metabolism is a significant impediment to the bioavailability
of many orally administered drugs. For these drugs, first-pass metabolism is not limited to the liver,
the major site of metabolism, but other organs and tissues are involved, such as the gastrointestinal
tract, blood, and vascular endothelium [37]. TU is an ester prodrug and is subject to significant
first-pass metabolism [12]. Both intestinal and hepatic first-pass metabolism can markedly decrease
the oral bioavailability of TU [9,10]. Herein, we have discriminated the contribution of hepatic and
intestinal tissues to the first-pass metabolism of oral TU, which represents the main obstacle for the
bioavailability of TU. This can thereby support the determination of an appropriate strategy to enhance
the bioavailability of TU.
In the current study, it was estimated that 91% of TU can escape hepatic first-pass metabolism
(FH = 0.915 ± 0.009), as predicted from the hydrolysis profile in hepatic microsomal fraction in
the presence of NADPH (Figure 2). To note, the hydrolysis of TU in the presence of NADPH is
a summation of NADPH-independent (carboxylesterase) and NADPH-dependant (5α-reductase)
enzymatic activity [38]. In addition, it should be noted that esterase activity is not limited to the
microsomal fraction. In fact, it has been depicted that microsomal fraction encompasses around 60% of
total esterase activity in human liver homogenate, while cytosolic fraction accounts for approximately
20% of esterase activity [39]. The incorporation of cytosolic esterase activity to the observed hydrolysis
profile of TU in liver microsomes can further decrease the fraction that could escape hepatic metabolism
to 89%. Nevertheless, it seems that hepatic first-pass metabolism is not the main determinant for the
low reported oral bioavailability of TU, since 91% was estimated to escape this metabolism.
In contrast, based on the hydrolysis profile of TU in Caco-2 cell homogenate (Figure 3), it can be
derived that a high percentage of the orally absorbed TU would be hydrolysed in the intestinal wall.
The fraction of TU that can escape intestinal metabolism was predicted to be 11.4% (FG = 0.114 ± 0.02).
Accordingly, the fraction that could escape intestinal metabolism is significantly lower than fraction
that could escape hepatic metabolism (p < 0.0001, Figure 4).
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Taking together the predicted profiles of hepatic and intestinal metabolism of TU, it can be
estimated that the oral bioavailability of TU would not exceed 10%, assuming complete absorption
from the intestinal lumen. However, it is generally accepted that ester prodrugs are exposed to
extensive hydrolysis in the intestinal lumen [40]. This can substantially decrease the oral bioavailability
of TU below 10%, thereby delivering low levels of testosterone to the systemic circulation. Indeed,
following the oral administration of TU in humans, the reported absolute bioavailability of testosterone
was as low as 6.8% [1]. In that study, as well as in others [11–13], it was suggested that the fraction
of TU that escaped first-pass metabolism was delivered to the systemic circulation via the intestinal
lymphatic system. Through this pathway, the fraction of TU that could be metabolised during the
first pass in the liver is saved. Therefore, the bioavailability is improved, as previously demonstrated
for several other lipophilic ester prodrugs [31]. However, as predicted in the current study, hepatic
metabolism has a minor contribution to the metabolic loss of TU compared to intestinal metabolism
(Figure 4). In fact, it seems possible that the incorporation of TU within chylomicrons in intestinal
enterocytes could preserve TU, at least partly, from hydrolysis in human intestines as well as in the
liver. A similar mechanism was suggested for TU absorption from the intestinal wall of rats [7]. Hence,
it can be suggested that co-administering TU with an intestinal carboxylesterase enzyme-inhibitor
could significantly increase the fraction of TU available for intestinal lymphatic transport, thereby
increasing the systemic bioavailability.
In addition, Caco-2 cell homogenates were previously proposed as a valid tool to assess the
stability of ester prodrugs [30,41]. In the current study, the hydrolysis profile of TU in Caco-2 cell
homogenate was successfully applied as a novel approach to predict the fraction of TU that could
escape intestinal metabolism. The predicted values fit very well with the bioavailability reported in
in vivo and clinical studies [9,11–13]. While the use of Caco-2 cell homogenate has provided a new
insight into the prediction of intestinal first-pass metabolism, further research should be undertaken to
investigate the application of this approach to ester prodrugs attached to chemically-divert promoieties.
Furthermore, it is important to bear in mind that Caco-2 cells have physiological differences compared
to the absorptive enterocytes in the human small intestine. Imai et al. have demonstrated differences
in the expression of ester-hydrolysing carboxylesterase isozymes, carboxylesterase-1 (CE-1) and
carboxylesterase-2 (CE-2). CE-1 is the main hydrolysing enzyme in Caco-2 cells, while the human small
intestine primarily expresses CE-2 [42]. Substrates with small alcohol groups and large acyl groups
are preferably hydrolysed by CE-1. In contrast, CE-2 favours substrates with small acyl group [43].
Nevertheless, CE-1 has a large flexible pocket that allows the hydrolysis of structurally-divers substrates,
including those with large alcohol groups [44]. This might explain the hydrolytic activity of Caco-2 cell
homogenate on TU in the current study, despite being a substrate with a relatively large alcohol group
(Figure 1).
5. Conclusions
In conclusion, compared to the liver, the intestinal wall is the major site where the absorbed
fraction of TU is extensively metabolised. It seems that intestinal lymphatic transport can decrease the
exposure of TU to intestinal hydrolysing enzymes as well as circumventing hepatic first-pass metabolism.
However, further studies are required to explore the metabolism of TU in vivo. Furthermore, the authors
recommend investigating the impact of using an intestinal enzyme-inhibitor on the bioavailability of
oral TU. Moreover, it appears that Caco-2 cell homogenate can be used to predict intestinal first-pass
metabolism of particular ester prodrugs.
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